Biomea Fusion shares surge 11.07% intraday after positive COVALENT-111 trial results show durable glycemic and C-peptide improvements.

Biomea Fusion surged 11.07% intraday following the presentation of COVALENT-111 trial results at the WCIRDC 2025, demonstrating durable glycemic and C-peptide improvements with Icovamenib in insulin-deficient Type 2 Diabetes patients. The phase 2 data showed statistically significant HbA1c reductions and increased insulin secretion, with higher efficacy observed in longer treatment durations. These results highlight the drug’s potential as a beta-cell-targeting therapy, aligning with the stock’s sharp intraday increase. Other news items, including unrelated developments about Nvidia, IBM, and Netflix, did not impact Biomea Fusion’s price movement.